Tempest Therapeutics, Inc. (TPST): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer and Principal Financial and Accounting Officer On October 26, 2026, Ms. Constance Ame
- Person
- Stephanie Horn-Warnock
- Title
- Chief Financial Officer
- Action
- appointed
- Effective
- effective immediately
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The filing provides the first public notice of the CFO change, a material corporate action that may influence short‑term trading sentiment.
Market read
The news is a primary disclosure of an executive change, offering limited but actionable insight for short‑term traders.
What to watch
The disclosed $450/hour consulting fee and 5% indirect cost allocation may affect cost structure if the arrangement extends long‑term.
Background
Tempest Therapeutics (NASDAQ: TPST) announced a leadership transition via a Form 8‑K filing, a standard regulatory disclosure for material corporate events.
Ticker impact
Tempest Therapeutics filed an 8‑K reporting the resignation of CFO Constance Ames and the appointment of Stephanie Horn‑Warnock as the new CFO, Treasurer and Corporate Secretary effective immediately.
likely modest pressure as the market prices in the transition and consulting fee arrangement
Executive turnover at the CFO level is material but not a catalyst for a directional move; the disclosed hourly consulting rate and indemnification suggest no immediate financial impact, leading to a neutral outlook.
Market effects
Minimal impact on the broader biotech sector; CFO changes are firm‑specific.
Limited to U.S. markets where the stock trades.
Low
Counterpoint
The new CFO's extensive consulting background could bring fresh operational efficiencies, potentially supporting upside if execution improves.
Key entities
- personConstance Ames
Outgoing Chief Financial Officer
- personStephanie Horn‑Warnock
Incoming CFO, Treasurer, and Corporate Secretary